EP0565704A1 - Synthetic peptides corresponding to portions of hiv-2 virus and methods of using in an improved assay - Google Patents

Synthetic peptides corresponding to portions of hiv-2 virus and methods of using in an improved assay

Info

Publication number
EP0565704A1
EP0565704A1 EP92924201A EP92924201A EP0565704A1 EP 0565704 A1 EP0565704 A1 EP 0565704A1 EP 92924201 A EP92924201 A EP 92924201A EP 92924201 A EP92924201 A EP 92924201A EP 0565704 A1 EP0565704 A1 EP 0565704A1
Authority
EP
European Patent Office
Prior art keywords
peptide
hiv
antibodies
sample
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92924201A
Other languages
German (de)
French (fr)
Other versions
EP0565704A4 (en
Inventor
Dinesh O. Shah
Andrew Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dade International Inc
Original Assignee
Baxter Diagnostics Inc
Dade International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Diagnostics Inc, Dade International Inc filed Critical Baxter Diagnostics Inc
Publication of EP0565704A1 publication Critical patent/EP0565704A1/en
Publication of EP0565704A4 publication Critical patent/EP0565704A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to synthetic peptides
  • HIV-2 is a virus related to HIV-1. Guyader et al.. Nature 326: 662-669 (1987). The complete nucleotide
  • antigenic peptides can have at its N-terminus either a H of the amino terminal NH 2 group of the peptide or an additional amino acid bonded to the amino terminal NH 2 group of the peptide, the
  • a peptide may by its self be antigenic, in coupling the peptide to various solid phases the antigenicity may be effected. This change in antigenicity may result in a solid phase that it not useful for conducting an immunoassay. In conducting an immunoassay the ability of the solid phase immunoreactant to detect HIV-2 antibodies in low concentrations is required, as these antibodies may exist in low concentration in the bodily fluid.
  • the present invention relates to certain synthetic peptides corresponding to a portion of the glyco-protein gp-41 encoded by HIV-2 env gene, having the basic sequence disclosed by Vahlne et al.
  • the improvement discovered by the inventors involves adding a Lysine substantially adjacent to either terminus of the peptide for coupling on to the solid phase and by adding a Glycine between the added Lysine and -Aspartic acid of the Vahlne et al. peptide, if Lysine is added to the N-terminus of the peptide.
  • this peptide modified for handling convenience showed improved sensitivity in an immunoassay.
  • this invention relates to an antigenic'peptide of the formula: (Sequence Id. No:l) wherein the improvement involves adding a Lysine substantially adjacent to either terminus of said peptide and adding a Glycine between the added Lysine and Aspartic acid, if Lysine is added to the N-terminus.
  • this invention relates to an antigenic peptide of the formula: (Sequence Id. No:2) wherein the improvement involves adding a Lysine substantially adjacent to either terminus of said peptide and adding a Glycine between the added Lysine and Aspartic acid if Lysine is added to the N-terminus.
  • the invention can be further defined as peptides having: a sequence of 26 amino acids (Sequence Id. No:3) 27 amino acids having (Sequence Id. No:4) as described in the sequence listing; 25 amino acids (Sequence Id. No:5) ; 26 amino acids (Sequence Id. No:6).
  • peptides can be used for detecting antibodies to HIV-2 in a sample.
  • the method involves contacting the sample with the peptide under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2 present in the sample, if such antibodies are present in the sample, and measuring the formation, if any of the•immunological complex to determine the presence of antibodies to HIV-2 in the sample..
  • the present invention provides improved peptides corresponding to a region of the transmembrane glyco-protein gp-41 of HIV-2 which has been synthesized and tested for immunoreactivity to HIV-2 positive serum samples as shown by Vahlne et al., (U.S. Patent No. 4,812,556 incorporated by reference).
  • the Vahlne et al. peptide has the following amino acid sequence: (Seq. Id. No:l) (Seq. Id.
  • No:2 can have at its N-terminus either a H of the amino * terminal NH 2 group of the peptide or an additional amino acid bonded to the amino terminal NH 2 group of the peptide, the additional amino acid being selected to facilitate coupling of the peptide to a carrier protein and at C-terminus either a OH or NH 2 .
  • Lysine can be incorporated at either end of the peptide for covalent coupling to the solid phase.
  • the Lysine is positioned to be substantially adjacent to either terminus.
  • substantially adjacent means within one or two amino acids of the terminus.
  • the modified peptides may have the amino acid sequences as shown in (Sequence Id. Nos:3-6)
  • Peptides were synthesized in the amide form on a Milligen-Biosearch 9600 model peptide synthesizer using fluorenylmethoxy carbonyl (FMOC) amino protection scheme and 1-3 diisopropyl carbodiimide coupling chemistry.
  • the amide form of the sequence was adopted because it could be expected to more closely mimic the biologically active analogue than the free acid form.
  • Activated amino acids were coupled to a 2,4- dimethoxy benzhydrylamine resin.
  • Peptide synthesis was monitored by ninhydrin analysis for all amino acids except proline for which an Isatin test was performed.
  • the synthesized peptide was cleaved from the resin by Reagent R, which comprises trifluoroacetic acid, thioanisole, ethanedithiol and anisol in a volumetric ratio of 90:5:3:2.
  • Peptides cleaved from resins were purified by high performance liquid chromatography (HPLC) , and characterized by Porton PI 20 90 E Integrated Micro Sequencing system to confirm the correct sequence. Purity was ascertained by HPLC on a reverse phase colu n using a linear gradient ((A) 0.1 trifluoroacetic acid in H J, (B)0.1% trifluoroacetic acid in CH-»CN) of 5% to 60% (B) in 45 minutes. Absorbance was followed at 230 nm. The peptides made by this process have the amino acid sequence as shown in (Sequence Id. No:3).
  • peptides were covalently coupled to carboxyl functionalized magnetic particles according to the following procedure: 1 ml of 2.5% weight/volume approximately 5 ⁇ m paramagnetic particles were separated on a magnetic separator in a 5 ml size disposable sterile cryogenic vial (corning, cat #25708). The supernatant was removed and.the particles resuspended with 1 ml of 70% ethanol for 10 minutes. The particles were then separated as before and supernatant was removed. The particles were resuspended in 1 ml of 0.1 M phosphate buffer, pH 5.5. The particles were separated as before and supernatant was removed. Further washing procedure with phosphate buffer was repeated twice as before and supernatant removed.
  • the covalently coupled peptide particles were then separated on a magnetic separator. Supernatant was removed and the particles were resuspended in isotonic buffered saline with 0.05% Tween 20 detergent. The particles were further separated and resuspended three times in isotonic buffered saline. The coated particles were then resuspended in isotonic buffered saline at final particles concentration of 0.25% weight to volume. It should be noted that the C-terminus can be comprised of either amide or acid groups depending on the desired end use.
  • Peptide were also passively coated onto paramagnetic microparticles according to the following procedure: 1 ml of 2.5% of weight/volume approximately 5 ⁇ m paramagnetic particles were separated on a magnetic separator in a 5 ml size disposable sterile cryogenic vial (corning, cat #25708) . The supernatant was removed and the particles resuspended with 1 ml of 70% ethanol for 10 minutes. The particles were then separated as before and supernatant was removed. The particles were resuspended in 1 ml of 0.1 M CHES buffer (2-(N-Cyclohexylamino) ethansulfonic acid) at pH 9.3. The particles were separated as before and supernatant was removed. Further, washing procedure with CHES buffer was repeated twice as before and supernatant removed.
  • EXAMPLE 1 A paramagnetic particle assay using particles coated with peptide prepared as previously described was performed as follows: Human serum or plasma was diluted 1:100 in well buffer (20% Neonate Calf Serum, 1.06 M Sodium Chloride, 0.03 M Tris-HCL, pH 7.4, 0.018 ° M Phosphate buffer, pH 7.4 + or - 0.3, 0.09% Sodium Azide, and 1.01% NP-40) .
  • the particles in the wells were washed with 100 ⁇ l phosphate buffered 0 saline and Tween-20 (2.06 g sodium phosphate dibasic, 0.318 g sodium phosphate monobasic 0.5 ml Tween-20, 8.76 g sodium chloride, and 1.0 g sodium azide per liter; pH 7.4).
  • the paramagnetic particles were held in the microtiter 5 plate well via a magnetic field applied to the bottom of the plate. Particles were washed in this manner six times.
  • Particles in each well were resuspended in 30 ⁇ l of particles resuspension buffer (4.346 g sodium 0 phosphate dibasic, 0.524 g sodium phosphate monobasic, 8.76 g sodium chloride, and 1 g sodium azide per liter; pH 7.4) 20 ⁇ l of goat antihuman IgG (H+L) conjugated ,9-Galactosidase (conjugate) and diluted 1:2000 in conjugate dilution buffer (0.1 M Tris-HCL pH 7.5, 0.5 M sodium chloride, 5% glycerol, 5.25 mM magnesium chloride, 0.1% sodium azide and 20% neonate calf sera pH 7.5 + or - 0.3) was then added to the wells.
  • particles resuspension buffer 4.346 g sodium 0 phosphate dibasic, 0.524 g sodium phosphate monobasic, 8.76 g sodium chloride, and 1 g sodium azide per liter; pH 7.4
  • 4-methyl-umbelliferyl-3-D-galactoside was added to each well (0.178 MUG, 3.58 g tricine, 5.1 ml dimethyl sulfoxide, 30 ml methyl alcohol, 0.2 g sodium azide, 0.5 ml Tween-20, per liter, pH 8.5).
  • the presence of ,9-galactosidase (ie: conjugate) in the wells triggered the cleavage of MUG to generate a fluorescent cou arin product.
  • This reagent and conjugate were used as a sensitive detection system. Fluorescence (excitation wavelength 400 nm/emmision wavelength 450 nm) was measured at two time intervals (i.e. 2 and 14 minutes) post MUG addition.
  • the difference between the two values was a kinetic measurement of fluorescent product generation and is a direct measurement of conjugate and human IgG/IgM bound to the particles. Fluorescent values were converted to nM coumarin values using various concentrations of coumarin itself and its resultant fluorescence to establish a standard curve.
  • HIV-2 POS HIV-2 POS
  • HIV-2 POS HIV-2 POS
  • HIV-2 POS HIV-2 POS
  • HIV-2 POS HIV-2 POS
  • the modified peptide passively as well as covalently coupled on magnetic particles, show significantly better sensitivity compared to unmodified peptide coated onto particles under identical coating and test conditions. This better sensitivity would allow the detection of HIV-2 antibody in lower concentrations in the patent sample.

Abstract

L'invention concerne des peptides synthétiques du virus VIH-2 ainsi qu'un procédé d'utilisation de ces peptides synthétiques dans une immunoanalyse améliorée de détection d'un anticorps contre VIH-2. L'invention concerne également le peptide antigénique ayant la formule (séquence n° 1 ou 2), l'amélioration consistant à ajouter de la lysine à un endroit sensiblement adjacent à la terminaison N ou C du peptide et à ajouter un glycine entre la lysine et l'acide aspartique si la lysine et ajoutée sur la terminaison N du peptide antigénique.The invention relates to synthetic peptides of the HIV-2 virus and a method of using these synthetic peptides in an improved immunoassay for the detection of an antibody against HIV-2. The invention also relates to the antigenic peptide having the formula (sequence No. 1 or 2), the improvement consisting in adding lysine at a location substantially adjacent to the N or C termination of the peptide and in adding a glycine between the lysine and aspartic acid if lysine is added to the N-terminus of the antigenic peptide.

Description

SYNTHETIC PEPTIDES CORRESPONDING TO PORTIONS OF HIV-2 VIRUS AND MErøODS OF USING IN AN IMPROVED ASSAY
$ BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to synthetic peptides
10 and method to use these synthetic peptides in an improved im unoassay for antibodies to HIV-2. 2. Description of the Prior Art
HIV-2 is a virus related to HIV-1. Guyader et al.. Nature 326: 662-669 (1987). The complete nucleotide
15 sequence of HIV-2 shows a genetic sequence ho ology with HIV.-l of 42% I . However, studies have showed that patients with HIV-2 infection were not identified by serologic test which detect HIV-1. Certain HIV-2 antigens have been indentified as being recognized by
20 antibodies in the sera of patients infected by HIV-2 infection. These antigens may be produced either recombinantly or synthetically. See e.g. Vahlne et al., U.S. Patent No. 4,812,556. In the '556 patent, Vahlne disclosed the a ino acid sequence of certain
25 antigenic peptides. These antigenic peptide sequences (Seq. Id. No:l) (Seq. Id. No:2) can have at its N-terminus either a H of the amino terminal NH2 group of the peptide or an additional amino acid bonded to the amino terminal NH2 group of the peptide, the
30 additional amino acid being selected to facilitate coupling of the peptide to a carrier protein and at C-terminus either a OH or NH2.
Although a peptide may by its self be antigenic, in coupling the peptide to various solid phases the antigenicity may be effected. This change in antigenicity may result in a solid phase that it not useful for conducting an immunoassay. In conducting an immunoassay the ability of the solid phase immunoreactant to detect HIV-2 antibodies in low concentrations is required, as these antibodies may exist in low concentration in the bodily fluid.
SUMMARY OF THE PRESENT INVENTION
The present invention relates to certain synthetic peptides corresponding to a portion of the glyco-protein gp-41 encoded by HIV-2 env gene, having the basic sequence disclosed by Vahlne et al. The improvement discovered by the inventors involves adding a Lysine substantially adjacent to either terminus of the peptide for coupling on to the solid phase and by adding a Glycine between the added Lysine and -Aspartic acid of the Vahlne et al. peptide, if Lysine is added to the N-terminus of the peptide. Surprisingly, this peptide modified for handling convenience showed improved sensitivity in an immunoassay.
In particular this invention relates to an antigenic'peptide of the formula: (Sequence Id. No:l) wherein the improvement involves adding a Lysine substantially adjacent to either terminus of said peptide and adding a Glycine between the added Lysine and Aspartic acid, if Lysine is added to the N-terminus. Additionally, this invention relates to an antigenic peptide of the formula: (Sequence Id. No:2) wherein the improvement involves adding a Lysine substantially adjacent to either terminus of said peptide and adding a Glycine between the added Lysine and Aspartic acid if Lysine is added to the N-terminus. More specifically, the invention can be further defined as peptides having: a sequence of 26 amino acids (Sequence Id. No:3) 27 amino acids having (Sequence Id. No:4) as described in the sequence listing; 25 amino acids (Sequence Id. No:5) ; 26 amino acids (Sequence Id. No:6).
These peptides can be used for detecting antibodies to HIV-2 in a sample. The method involves contacting the sample with the peptide under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2 present in the sample, if such antibodies are present in the sample, and measuring the formation, if any of the•immunological complex to determine the presence of antibodies to HIV-2 in the sample..
DETAILED DESCRIPTION OF THE INVENTION The present invention provides improved peptides corresponding to a region of the transmembrane glyco-protein gp-41 of HIV-2 which has been synthesized and tested for immunoreactivity to HIV-2 positive serum samples as shown by Vahlne et al., (U.S. Patent No. 4,812,556 incorporated by reference). The Vahlne et al. peptide has the following amino acid sequence: (Seq. Id. No:l) (Seq. Id. No:2) can have at its N-terminus either a H of the amino* terminal NH2 group of the peptide or an additional amino acid bonded to the amino terminal NH2 group of the peptide, the additional amino acid being selected to facilitate coupling of the peptide to a carrier protein and at C-terminus either a OH or NH2.
The inventor's observed that the presence of Lysine in the peptide facilitates its covalent coupling to a solid surface. Consequently, the inventors extended "ttve Vahlne et al. peptide by addition of Lysine. Lysine can be incorporated at either end of the peptide for covalent coupling to the solid phase. The Lysine is positioned to be substantially adjacent to either terminus. The phrase substantially adjacent means within one or two amino acids of the terminus.
In addition Glycine was added between Lysine and Aspartic acid of the Vahlne et al. peptide. Glycine was added to: 1) act as a spacer for better orientation of the peptide on the particles; and 2) to prevent the interaction between -COOH group of Asp and the NH group of Lysine. Thus, the modified peptides may have the amino acid sequences as shown in (Sequence Id. Nos:3-6)
Peptides were synthesized in the amide form on a Milligen-Biosearch 9600 model peptide synthesizer using fluorenylmethoxy carbonyl (FMOC) amino protection scheme and 1-3 diisopropyl carbodiimide coupling chemistry. The amide form of the sequence was adopted because it could be expected to more closely mimic the biologically active analogue than the free acid form. Activated amino acids were coupled to a 2,4- dimethoxy benzhydrylamine resin. Peptide synthesis was monitored by ninhydrin analysis for all amino acids except proline for which an Isatin test was performed. The synthesized peptide was cleaved from the resin by Reagent R, which comprises trifluoroacetic acid, thioanisole, ethanedithiol and anisol in a volumetric ratio of 90:5:3:2.
Peptides cleaved from resins were purified by high performance liquid chromatography (HPLC) , and characterized by Porton PI 20 90 E Integrated Micro Sequencing system to confirm the correct sequence. Purity was ascertained by HPLC on a reverse phase colu n using a linear gradient ((A) 0.1 trifluoroacetic acid in H J, (B)0.1% trifluoroacetic acid in CH-»CN) of 5% to 60% (B) in 45 minutes. Absorbance was followed at 230 nm. The peptides made by this process have the amino acid sequence as shown in (Sequence Id. No:3).
These peptides were covalently coupled to carboxyl functionalized magnetic particles according to the following procedure: 1 ml of 2.5% weight/volume approximately 5 μm paramagnetic particles were separated on a magnetic separator in a 5 ml size disposable sterile cryogenic vial (corning, cat #25708). The supernatant was removed and.the particles resuspended with 1 ml of 70% ethanol for 10 minutes. The particles were then separated as before and supernatant was removed. The particles were resuspended in 1 ml of 0.1 M phosphate buffer, pH 5.5. The particles were separated as before and supernatant was removed. Further washing procedure with phosphate buffer was repeated twice as before and supernatant removed.
To the slurry of particles was added 6 mg of Sulfo-N-Hydroxy Succinimide and 7 mg of i-Ethyl-3-(Dimethylaminopropyl) carbodiimide hydrochloride. The particles resuspended and left at room temperature for 5 minutes with occasional shaking. To the activated particles was added 125 ul solution of HIV-2 peptide (lmg/ml in 0.1 M phosphate buffer, pH 7.3) followed by the addition of 875 ul of 0.1 M phosphate buffer, pH 7.3. The particles were mixed thoroughly and then tumbled for 12-15 hours at room temperature.
The covalently coupled peptide particles were then separated on a magnetic separator. Supernatant was removed and the particles were resuspended in isotonic buffered saline with 0.05% Tween 20 detergent. The particles were further separated and resuspended three times in isotonic buffered saline. The coated particles were then resuspended in isotonic buffered saline at final particles concentration of 0.25% weight to volume. It should be noted that the C-terminus can be comprised of either amide or acid groups depending on the desired end use.
Peptide were also passively coated onto paramagnetic microparticles according to the following procedure: 1 ml of 2.5% of weight/volume approximately 5 μm paramagnetic particles were separated on a magnetic separator in a 5 ml size disposable sterile cryogenic vial (corning, cat #25708) . The supernatant was removed and the particles resuspended with 1 ml of 70% ethanol for 10 minutes. The particles were then separated as before and supernatant was removed. The particles were resuspended in 1 ml of 0.1 M CHES buffer (2-(N-Cyclohexylamino) ethansulfonic acid) at pH 9.3. The particles were separated as before and supernatant was removed. Further, washing procedure with CHES buffer was repeated twice as before and supernatant removed.
To the slurry of particles was added 875 ul of 0.1M CHES buffer and 125 ul of peptide solution (1 g/ml in 0.1M CHES buffer) . The particles were resuspended and then tumbled for 18 hours at room temperature. The passively adsorbed peptide particles were then separated on a magnetic separator, supernatant removed and particles resuspended in isotonic buffered saline with 0.05% Tween 20 detergent. The particle were further separated and resuspended three times in isotonic buffered saline. The coated particles are then resuspended in isotonic buffered saline at final particle concentration of 0.25% weight to volume. EXAMPLE 1 A paramagnetic particle assay using particles coated with peptide prepared as previously described was performed as follows: Human serum or plasma was diluted 1:100 in well buffer (20% Neonate Calf Serum, 1.06 M Sodium Chloride, 0.03 M Tris-HCL, pH 7.4, 0.018 ° M Phosphate buffer, pH 7.4 + or - 0.3, 0.09% Sodium Azide, and 1.01% NP-40) .
50 μl of the diluted sample was added to each well of a Pandex black microtiter plate. Samples were tested in replicates of at least 2. Paramagnetic 5 particles, coated with peptides as describe in example 1 or 2, were added to each well (20 μl) . The plate was then placed at 42°C for 30 minutes.
Upon completion of the incubation, the particles in the wells were washed with 100 μl phosphate buffered 0 saline and Tween-20 (2.06 g sodium phosphate dibasic, 0.318 g sodium phosphate monobasic 0.5 ml Tween-20, 8.76 g sodium chloride, and 1.0 g sodium azide per liter; pH 7.4). During the wash steps, the paramagnetic particles were held in the microtiter 5 plate well via a magnetic field applied to the bottom of the plate. Particles were washed in this manner six times.
Particles in each well were resuspended in 30 μl of particles resuspension buffer (4.346 g sodium 0 phosphate dibasic, 0.524 g sodium phosphate monobasic, 8.76 g sodium chloride, and 1 g sodium azide per liter; pH 7.4) 20 μl of goat antihuman IgG (H+L) conjugated ,9-Galactosidase (conjugate) and diluted 1:2000 in conjugate dilution buffer (0.1 M Tris-HCL pH 7.5, 0.5 M sodium chloride, 5% glycerol, 5.25 mM magnesium chloride, 0.1% sodium azide and 20% neonate calf sera pH 7.5 + or - 0.3) was then added to the wells. After incubation with conjugate for 15 minutes at 42°C the particles in the wells were washed six times with phosphate buffer saline and Tween-20 as described above to remove essentially all of the unbound conjugate. The Tween-20 in the wash solution enhanced the washing process and removed non specifically bound conjugate. Finally, 50 μl of a substrate solution of
4-methyl-umbelliferyl-3-D-galactoside (MUG) was added to each well (0.178 MUG, 3.58 g tricine, 5.1 ml dimethyl sulfoxide, 30 ml methyl alcohol, 0.2 g sodium azide, 0.5 ml Tween-20, per liter, pH 8.5). The presence of ,9-galactosidase (ie: conjugate) in the wells triggered the cleavage of MUG to generate a fluorescent cou arin product. This reagent and conjugate were used as a sensitive detection system. Fluorescence (excitation wavelength 400 nm/emmision wavelength 450 nm) was measured at two time intervals (i.e. 2 and 14 minutes) post MUG addition. The difference between the two values was a kinetic measurement of fluorescent product generation and is a direct measurement of conjugate and human IgG/IgM bound to the particles. Fluorescent values were converted to nM coumarin values using various concentrations of coumarin itself and its resultant fluorescence to establish a standard curve.
EVALUATION OF TWO HIV-2 PEPTIDES COVALENTLY COUPLED TO PARTICLES IN HIV ASSAY*
TEST SAMPLES
HIV-2 POS.
HIV-2 POS.
HIV-1 POS. 1:100 85 65
NEG.CONTROL. 1:100 90 83
SAMPLE DILUENT 12 16
* Assay conditions were 0.05% particles suspension, Goat anti Human IgG-B Galactosidase conjugate. ** Assay signal is in fluorescent units.
EVALUATION OF TWO HIV-2 PEPTIDES PASSIVELY ADSORBED ON PARTICLES IN HIV ASSAY*
TEST SAMPLES
HIV-2 POS.
HIV-2 POS.
NEG.CONTROL. 1:100 23 38
SAMPLE DILUENT 22 13
* Assay conditions were 0.05% particles suspension. Goat anti Human IgG-B Galactosidase conjugate. ** Assay signal is in fluorescent units.
The modified peptide, passively as well as covalently coupled on magnetic particles, show significantly better sensitivity compared to unmodified peptide coated onto particles under identical coating and test conditions. This better sensitivity would allow the detection of HIV-2 antibody in lower concentrations in the patent sample.
Although the invention has been described primarily in connection with special and preferred embodiments, it will be understood that it is capable of modification without departing from the scope of the invention. The following claims are intended to cover all variations, uses, or adaptations of the invention, following, in general, the principles thereof and including such departures from the present disclosure as come within known or customary practice in the field to which the invention pertains, or as are obvious to persons skilled in the field.
SEQUENCE LISTING
(1) GENERAL INFORMAΗON:
(i) APPLICANT: Shah, Dinesh 0 Schneider, Andrew
(ii) TITLE OF INVENTION: Synthetic Peptides Corresponding to a Portion of HIV-2 Virus and Method To Use The Same in an Improved Immunoassay
(Hi) NUMBER OF SEQUENCES: 6
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Baxter Diagnostics Inc.
(B) STREET: One Baxter Parkway, DF2-2E
(C) CITY: Deerfield
(D) STATE: Illinois
(E) COUNTRY: usa
(F) ZIP: 60015
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIHCAπON:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Barta, Kent
(B) REGISTRATION NUMBER: 29,042
(C) REFERENCE DOCKET NUMBER: 91I83A
(ix) TELECOMMUNICAΗON INFORMATION: (A) TELEPHONE: 708/948-3308 (2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPΗON: SEQ ID NO:l:
Asp Gin Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gin Val Cys 1 5 10 15
His Thr Thr Val Pro Trp Val Asn 20
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPΗON: SEQ ID NO:2:
Asp Gin Ala Arg Leu Asn Ser Tip Gly Cys Ala Phe Arg Gin Val Cys 1 5 10 15
His Thr Thr Val Pro Trp Val Asn Cys 20 25 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Lys Gly Asp Gin Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gly 1 5 10 15
Val Cys His Thr Thr Val Pro Trp Val Asn 20 25
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPΗON: SEQ ID NO:4:
Lys Gly Asp Gin Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gly 1 5 10 15
Val Cys His Thr Thr Val Pro Trp Val Asn Cys 20 25 (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPΗON: SEQ ID NO:5:
Asp Gin Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gin Val Cys 1 5 10 15
His Thr Thr Val Pro Trp Val Asn Lys 20 25
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPΗON: SEQ ID NO:6:
Asp Gin Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gin Val Cys 1 5 10 15
His Thr Thr Val Pro Trp Val Asn Cys Lys 20 25

Claims

We claim:
1. An antigenic peptide of the formula: (Sequence Id. No:l) the improvement comprising: a) adding a Lysine substantially adjacent to either terminus of said peptide; b) adding a Glycine between said added Lysine and Aspartic acid if Lysine is added to the N-terminus of said antigenic peptide.
2 A method for detecting antibodies to HIV-2 in a sample comprising: a) contacting-said sample with the peptide of claim 1 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the' formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
3. An antigenic peptide of the formula: (Sequence Id. No:2) the improvement comprising: a) adding a Lysine substantially adjacent to either terminus of said antigenic peptide; b) adding a Glycine between said added Lysine if Lysine is added to the N-terminus.
4. A method for detecting antibodies to HIV-2 in a sample comprising: a) contacting said sample with the peptide of claim 2 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
5. A synthetic peptide compound capable of binding to antibodies to HIV-2 consisting of a peptide selected from the group of peptides represented by the following N-terminal to C-terminal amino acid sequences:
a. Sequence Id : No 3 b. Sequence Id : No 4 b. Sequence Id : No 5 c. Sequence Id : No 6
6. A method for detecting antibodies to HIV-2 in a sample comprising: a) contacting said sample with the peptide of claim 5 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
EP92924201A 1991-11-04 1992-11-04 Synthetic peptides corresponding to portions of hiv-2 virus and methods of using in an improved assay Withdrawn EP0565704A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78991491A 1991-11-04 1991-11-04
US789914 1991-11-04

Publications (2)

Publication Number Publication Date
EP0565704A1 true EP0565704A1 (en) 1993-10-20
EP0565704A4 EP0565704A4 (en) 1995-10-25

Family

ID=25149091

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92924201A Withdrawn EP0565704A4 (en) 1991-11-04 1992-11-04 Synthetic peptides corresponding to portions of hiv-2 virus and methods of using in an improved assay

Country Status (5)

Country Link
EP (1) EP0565704A4 (en)
JP (1) JPH06503843A (en)
AU (1) AU657590B2 (en)
CA (1) CA2099367A1 (en)
WO (1) WO1993009252A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023973A2 (en) * 1994-03-02 1995-09-08 Abbott Laboratories Hiv immunoassay utilizing recombinant protein and synthetic peptide reagents
US5977299A (en) * 1997-04-07 1999-11-02 Dade Behring Marburg Gmbh Activated peptides and conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267802A2 (en) * 1986-11-14 1988-05-18 Genetic Systems Corporation Synthetic antigen for the detection of aids-related disease
WO1991013909A1 (en) * 1990-03-15 1991-09-19 Proteus Molecular Design Limited Synthetic polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812556A (en) * 1987-05-18 1989-03-14 Virovahl Synthetic peptide antigen for the detection of HIV-2 infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267802A2 (en) * 1986-11-14 1988-05-18 Genetic Systems Corporation Synthetic antigen for the detection of aids-related disease
WO1991013909A1 (en) * 1990-03-15 1991-09-19 Proteus Molecular Design Limited Synthetic polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9309252A1 *

Also Published As

Publication number Publication date
WO1993009252A1 (en) 1993-05-13
JPH06503843A (en) 1994-04-28
AU3059892A (en) 1993-06-07
CA2099367A1 (en) 1993-05-05
EP0565704A4 (en) 1995-10-25
AU657590B2 (en) 1995-03-16

Similar Documents

Publication Publication Date Title
AU648912B2 (en) Immunoassay for non-A non-B hepatitis
KR100240514B1 (en) Determination of a specific immunoglobulin using multiple antigens
EP1328811B1 (en) Hcv mosaic antigen composition
JPH06247997A (en) Hcv peptide antigen and method for measuring hcv
AU657590B2 (en) Synthetic peptides corresponding to portions of HIV-2 virus and methods of using in an improved assay
JP2813768B2 (en) Foot-and-mouth disease diagnostic peptide and foot-and-mouth disease diagnostic antigen containing the peptide
AU660752B2 (en) Immunoassay using synthetic HTLV-11 peptides
JP3404035B2 (en) Cysteine thiol protected peptides for use in immunoassays
JP2001512037A (en) Synthetic antigens for the detection of antibodies immunoreactive with the HIV virus
AU623949B2 (en) Synthetic peptide derivatives of gp41 glycoprotein of HIV
JP2655205B2 (en) Assay for non-A non-B hepatitis
EP0628079A1 (en) Hepatitis c virus peptides
CA2223090C (en) Improved hapten-peptide conjugates to detect anti-hiv-1 or anti-hiv-2 antibodies
JP2002511853A (en) HIV antibody detection method and antigen used therefor
CA2004288A1 (en) Peptides
US20020150990A1 (en) Hepatitis C virus peptides
DE DK et al. HCV MOSAIK ANTIGEN ZUSAMMENSETZUNG COMPOSITION D’ANTIGENE MOSAIQUE DU VIRUS DE L’HEPATITE C (VHC)
JPH04221398A (en) Antibody to non-a, non-b hepatitis virus and immunochemically reactive peptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DADE INTERNATIONAL INC.

RHK1 Main classification (correction)

Ipc: C07K 7/10

A4 Supplementary search report drawn up and despatched

Effective date: 19950912

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB IT

17Q First examination report despatched

Effective date: 19960913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970303